Published 1:53 PM, 7 Apr 2011
By a staff reporter, with Reuters
The pharmaceutical giant had hoped to get approval for the vaccine to be used by women between the ages of 27 and 45.
Merck said that the Food and Drug Administration concluded that Gardasil has not been shown to prevent HPV-related cervical cancers in women over the age of 26 and the drug’s label has been updated to reflect that decision.
Gardasil is approved for use in girls and young women 9 through 26 years of age.
Merck has the rights to market Gardasil outside Australia, with royalties paid to CSL on sales made.
CSL received royalty payments of $45 million in the first half.
At 1340 AEST, shares in CSL had fallen 0.22 per cent to $36.46, against a 0.11 per cent drop in the benchmark index.